ECEL1基因PSCSI-GFP慢病毒载体的构建

何剑; 廖红伍; 阳学风

doi:10.3969/j.issn.1001-5256.2019.06.021

ECEL1基因PSCSI-GFP慢病毒载体的构建

DOI: 10.3969/j.issn.1001-5256.2019.06.021

基金项目:

国家自然科学基金面上项目(81373465)；湖南省自然科学省市联合基金(2016JJ5010)；湖南省卫生计生委科研课题(A2017015)；

详细信息

中图分类号: Q78
计量
- 文章访问数: 1427
- HTML全文浏览量: 10
- PDF下载量: 285
- 被引次数: 0
出版历程
- 收稿日期: 2018-12-20
- 出版日期: 2019-06-20

Construction of PSCSI-GFP lentiviral vector for the endothelin-converting enzyme-like 1 gene

Research funding:

摘要

摘要: 目的设计并构建针对ECEL1基因的RNA干扰慢病毒载体。方法依照ECEL1基因为模板,设计RNA干扰靶点,根据选定的靶点序列,设计短发夹RNA（shRNA）干扰序列,在两端添加相应的限制性内切酶酶切位点,合成单链DNA oligo,退火缓冲液中配对形成双链DNA oligo。利用Age I和EcoR I双酶线性化GV115载体。把载体和DNA oligo相连接,其连接产物转化大肠杆菌感受态细胞,经PCR扩增并测序鉴定。再通过质粒抽提,转染,浓缩与纯化后获得重组的ECEL1基因RNAi慢病毒,用"HIV-1p24抗原ELISA法"测定样品滴度。选取检测合格的慢病毒感染人肝癌细胞（BEL-7404）,并设置对照组,荧光观察感染率。并使用Real-time PCR法及Western blot检测人肝癌细胞（BEL-7404）中ECEL1基因敲减后mRNA和蛋白质的表达量。2组间比较采用两独立样本t检验。结果（1）根据ECEL1基因模板设计后,选定psc48784片段作为RNA干扰靶点,制备双链DNA oligo,PCR鉴定阳性重组子并测序,验证psc48784为正确的克隆。经过质粒抽提,转...
- ECEL1基因 /
- 慢病毒载体 /
- 肝肿瘤
Abstract: Objective To design and construct the RNA interference (RNAi) lentiviral vector targeting the endothelin-converting enzyme-like 1 (ECEL1) gene. Methods The RNA interference target was designed with the ECEL1 gene as the template, and the short-hairpin RNA (shRNA) interference sequence was designed based on the selected target sequence. Enzyme cut sites for restriction endonuclease were added to both ends of this sequence to synthesize single-stranded DNA oligo, which was then paired in annealing buffer to form double-stranded DNA oligo. GV115 vectors were linearized by double digestion with Age I and EcoR I enzymes, and then they were connected with the DNA oligo; the grafted product transformed Escherichia coli receptor cells and was amplified, sequenced, and identified by PCR.The recombinant ECEL1 gene RNAi lentivirus was obtained by plasmid extraction, transfection, concentration, and purification, and HIV-1 p24 antigen ELISA was used to determine the titer of the recombinant RNAi lentivirus. Human hepatoma BEL-7404 cells were transfected with the qualified lentivirus, and a control group was set up. Fluorescence observation was performed to determine transfection rate. Real-time PCR and Western blot were used to measure the mRNA and protein expression of target gene after ECEL1 gene knockdown in human hepatoma BEL-7404 cells. The two-independent-samples t test was used for comparison between two groups. Results After the design with the ECEL1 gene as the template, the psc48784 fragment was selected as the target for RNAi; the double-stranded DNA oligo was prepared and the positive recons were identified and sequenced by PCR, and the results showed that psc48784 was the correct clone. The ECEL1 gene RNAi lentivirus was successfully constructed after plasmid extraction, transfection, concentration, and purification and was qualified for physical test and sterility test. HIV-1 p24 antigen ELISA showed that the ECEL1 gene RNAi lentivirus had a virus titer of 3 E+ 8 TU/ml, suggesting that the qualified ECEL1 gene RNAi lentivirus with a high titer was successfully constructed. After the human hepatoma BEL-7404 cells were transfected with the ECEL1 gene RNAi lentivirus, fluorescence observation showed a transfection efficiency of80% and a stable state of cells. Real-time PCR and Western blot showed significant reductions in the mRNA and protein expression of the ECEL1 gene in human hepatoma BEL-7404 cells in the experimental group (P < 0. 05) , and the knockdown efficiency reached 70. 5%.Conclusion The ECEL1 gene PSCSI-GFP lentiviral vector is successfully constructed, and stable virus samples with a high titer are obtained. The stable human hepatoma BEL-7404 cells with ECEL1 gene knockdown are also obtained.
- ECEL1 gene /
- lentiviral vector /
- liver neoplasms

HTML全文

参考文献(21)

[1]KIRYU-SEO S, NAGATA K, SAIDO TC, et al.New insights of a neuronal peptidase DINE/ECEL1:Nerve development, nerve regeneration and neurogenic pathogenesis[J].Neurochem Res, 2018.[Epub ahead of print]

[2]KIRYU-SEO S, SASAKI M, YOKOHAMA H, et al.Damageinduced neuronal endopeptidase (DINE) is a unique metallopeptidase expressed in response to neuronal damage and activates superoxide scavengers[J].Proc Natl Acad Sci USA, 2000, 97 (8) :4345-4350.

[3]NAGATA K, TAKAHASHI M, KIRYU-SEO S, et al.Distinct functional consequences of ECEL1/DINE missense mutations in the pathogenesis of congenital contracture disorders[J].Acta Neuropathol Commun, 2017, 5 (1) :83.

[4]LI YP, SONG LP, QIU SD, et al.The appliance of lentivirus vector in cancer theray[J].Mod Oncol, 2006, 14 (12) :1615-1617. (in Chinese) 李跃萍, 宋丽萍, 邱曙东, 等.慢病毒载体在肿瘤基因治疗中的应用[J].现代肿瘤医学, 2006, 14 (12) :1615-1617.

[5]FRANKEL AD, YOUNG JA.HIV-1:Fifteen proteins and an RNA[J].Annu Rev Biochem, 1998, 67:1-25.

[6]WYSOCZYNSKI M, RATAJCZAK MZ.Lung cancer secreted microvesicles:Underappreciated modulators of microenvironment in expanding tumors[J].Int J Cancer, 2009, 125 (7) :1595-1603.

[7]ZHANG L, LIU QY, HU T, et al.The construction of high-efficiency packaging system of the 3rd lentivirus[J].Genom Appl Biol, 2009, 28 (2) :326-330. (in Chinese) 张磊, 刘庆友, 胡天, 等.第三代慢病毒高效率包装系统的建立[J].基因组学与应用生物学, 2009, 28 (2) :326-330.

[8]BRECKPOT K, AERTS JL, THIELEMANS K.Lentiviral vectors for cancerimmunotherapy:Transforming infectious particles into therapeutics[J].Gene Ther, 2007, 14 (11) :847-862.

[9]ESCORS D, BRECKPOT K.Lentiviral vectors in gene therapy:Their current status and future potential[J].Arch Immunol T-her Exp (Warsz) , 2010, 58 (2) :107-119.

[10]KAFRI T, BLOMER U, PETERSON DA, et al.Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors[J].Nat Genet, 1997, 17 (3) :314-317.

[11]MAO Y, YAN R, LI A, et al.Lentiviral vectors mediate long term and high efficiency transgene expression in hek 293Tcells[J].Int J Med Sci, 2015, 12 (5) :407-415.

[12]KAHLERT C, KLUPP F, BRAND K, et al.Invasion front-specific expression and prognostic significance of microRNA in colorectal liver metastases[J].Cancer Sci, 2011, 102 (10) :1799-1807.

[13]LIN Y, DESAI A, GESRSON SL.Lentiviruses:Vectors for cancer gene therapy[M].In:Roth J, editor.Gene Based Therapies for Cancer, Current Cancer Research.Springer Science, 2010.

[14]VUCIC D, FAIRBROTHER WJ.The inhibitor of apoptosis proteins as therapeutic targets in cancer[J].Clin Cancer Res, 2007, 13 (20) :5995-6000.

[15]KOCK N, KASMIEH R, WEISSLEDER R, et al.Tumor theraphy media-ted by lentiviral expression of sh Bcl-2 and S-TRAIL[J].Neo-plasia, 2007, 9 (5) :435-442.

[16]ZHAO B, YANG C, YANG S, et al.Construction of conditional lentivir-Us-mediated shRNA vector targeting the human Mirk gene and identification of RNAi efficiency in rhabdomyosarcoma RD cells[J].Int J Oncol, 2013, 43 (9) :1253-1259.

[17]LING X, ARLINGHAUS RB.Knockdown of STAT3 expression by immunocompetent mice[J].Cancer Res, 2015, 65 (7) :2532-2536.

[18]SUMIMOTO H, MIYAGISHI M, MIYOSHI H, et al.Inhibition of growth and invasive ability of melanoma RNA interference[J].Oncogene, 2014, 23 (36) :6031-6039.

[19]PUTRAL LN, BYWATER MJ, GU W, et al.RNA interference against hunman papilloomavirus oncogenes in cervical cancer cells result in increased sensitivitity to cisplatin[J].Mol Pharmacol, 2015, 68 (5) :1311-1319.

[20]YE XS, LIU T, GONG YP, et al.Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 singlefactor resistant cell line K562/MDR1[J].Leuk Res, 2009, 33 (8) :1114-1119.

[21]XIE SM, FANG WY, LIU Z, et al.Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin[J].Transl Med, 2008, 6 (1) :55-63.

施引文献

资源附件(0)

访问统计